A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma
- PMID: 16218042
- DOI: 10.1007/BF03347258
A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma
Abstract
Although quality of life (QoL) has become an important aspect of cancer rehabilitation, psychometric studies on thyroid cancer patients are rare. We performed a case-controlled study on QoL in patients with differentiated thyroid carcinoma (DTC). QoL was evaluated in 61 patients with a history of DTC diagnosed from < 1 to 23 yr earlier. An undetectable thyroglobulin (Tg) level after recombinant human TSH (rhTSH) testing was considered the best predictor of cure. QoL was evaluated by means of a general psychiatric interview, the self-rating Kellner Symptoms Questionnaire (KSQ) and the Hamilton Depression Scale (HDS). QoL was also evaluated in a control group of subjects on L-T4 therapy with a non-toxic multinodular goiter diagnosed from < 1 to 25 yr earlier. DTC and control subjects were similar in age, male-female distribution and concomitant psychiatric therapies. Per-week dosage of L-T4 was higher in DTC patients than in controls (p < 0.01). In neither group of subjects was there any correlation between current TSH levels or interval from diagnosis and KSQ or HDS scores. Only in DTC patients was there a positive correlation between age and KSQ (p < 0.05) or HDS (p < 0.01) scores. There was a significant difference in overall KSQ scores between DTC (33.4 +/- 2.1) and control (24.5 +/- 1.9; p < 0.01) subjects. The subscales of KSQ showed a significant inter-group difference. HDS scores were higher in DTC subjects (35.8 +/- 1.0) than in controls (30.0 +/- 1.1; p < 0.01). HDS score was significantly (p = 0.02) higher in female than in male DTC patients. In patients with papillary carcinoma there was a positive correlation between the MACIS (metastases, age, completeness, invasiveness, size) score and KSQ (p = 0.01) or HDS (p < 0.01) scores. After rhTSH testing, detectable Tg levels were found in 13% of DTC patients. In Tg-positive patients, KSQ and HDS scores were not different from those of Tg-negative patients. After an 8-14 month period, a significant decrease in the KSQ scale somatization (p = 0.02) was found in a sub-set of 31 DTC patients. In conclusion, even in the age of rhTSH testing, DTC patients suffer an impairment of their QoL, as noted when short-term L-T4 withdrawal was the gold standard. Longitudinal evaluation seems to indicate a slight improvement in QoL when safe rhTSH testing is extensively used in the management of the disease.
Similar articles
-
Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.J Zhejiang Univ Sci B. 2011 Mar;12(3):163-73. doi: 10.1631/jzus.B1000382. J Zhejiang Univ Sci B. 2011. PMID: 21370500 Free PMC article.
-
The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.Clin Endocrinol (Oxf). 2003 May;58(5):556-61. doi: 10.1046/j.1365-2265.2003.01744.x. Clin Endocrinol (Oxf). 2003. PMID: 12699436
-
Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.Minerva Endocrinol. 2003 Sep;28(3):191-203. Minerva Endocrinol. 2003. PMID: 14605601
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
-
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.J Clin Endocrinol Metab. 2003 Apr;88(4):1433-41. doi: 10.1210/jc.2002-021702. J Clin Endocrinol Metab. 2003. PMID: 12679418 Review.
Cited by
-
Prognostic utility of BRAF mutation in papillary thyroid cancer.Mol Cell Endocrinol. 2010 May 28;321(1):86-93. doi: 10.1016/j.mce.2009.10.012. Epub 2009 Oct 31. Mol Cell Endocrinol. 2010. PMID: 19883729 Free PMC article. Review.
-
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.Onco Targets Ther. 2009 Jan 1;1:87-101. doi: 10.2147/ott.s3480. Onco Targets Ther. 2009. PMID: 21127756 Free PMC article.
-
Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea.Health Qual Life Outcomes. 2010 Sep 15;8:101. doi: 10.1186/1477-7525-8-101. Health Qual Life Outcomes. 2010. PMID: 20840792 Free PMC article.
-
The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study.PLoS One. 2009;4(1):e4191. doi: 10.1371/journal.pone.0004191. Epub 2009 Jan 14. PLoS One. 2009. PMID: 19142227 Free PMC article.
-
Quality of Life of Survivors of Thyroid Cancer Is Not Inferior to That in Subjects without Cancer: Long-Term after Over 5 Years.Endocrinol Metab (Seoul). 2022 Aug;37(4):664-673. doi: 10.3803/EnM.2022.1499. Epub 2022 Aug 29. Endocrinol Metab (Seoul). 2022. PMID: 36065647 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous